ANI Prepares For Cortrophin Launch
Company Anticipates FDA Approval By October
Executive Summary
US-based ANI Pharmaceuticals is looking to strengthen its leadership team and strategize a commercial approach for the launch of Cortrophin Gel, as it anticipates FDA approval by 29 October 2021. ANI reported a 2.4% increase in its generics business.
You may also be interested in...
What’s Next? Five Things To Look Out For In October
In October, Dr Reddy’s Laboratories and ANI Pharmaceuticals are among companies expecting to hear from the US Food and Drug Administration for key applications, as the annual joint conference of Medicines for Europe and the International Generic and Biosimilar medicines Association takes place in Athens, Greece.
ANI Transforms With Novitium And Sandoz Deals
US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches.
ANI Picks Up US Dermatology Brands From Sandoz
ANI Pharmaceuticals has added to its branded portfolio by acquiring several dermatology brands from Sandoz in the US.